$1.28 Billion is the total value of Camber Capital Management LP's 39 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was 35.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TEVA | Sell | TEVA PHARMACEUTICAL INDS LTD | $87,186,000 | +8.8% | 1,650,000 | -17.5% | 6.83% | -3.4% |
| HCA | Sell | HCA HOLDINGS INC | $42,000,000 | -29.6% | 800,000 | -36.0% | 3.29% | -37.4% |
| MNKKQ | Sell | MALLINCKRODT PUB LTD CO | $41,216,000 | -21.1% | 650,000 | -35.0% | 3.23% | -29.9% |
| MASI | Sell | MASIMO CORP | $34,820,000 | -16.4% | 1,275,000 | -10.5% | 2.73% | -25.7% |
| UNH | Sell | UNITEDHEALTH GROUP INC | $24,597,000 | -49.7% | 300,000 | -53.8% | 1.93% | -55.3% |
| ARIA | Sell | ARIAD PHARMACEUTICALS INC | $24,180,000 | -32.5% | 3,000,000 | -42.9% | 1.90% | -40.0% |
| HUM | Sell | HUMANA INC | $22,544,000 | -45.4% | 200,000 | -50.0% | 1.77% | -51.5% |
| MYL | Sell | MYLAN INC | $12,207,000 | -83.9% | 250,000 | -85.7% | 0.96% | -85.7% |
| NVAX | Sell | NOVAVAX INC | $10,192,000 | -43.1% | 2,250,000 | -35.7% | 0.80% | -49.5% |
| GNMK | Sell | GENMARK DIAGNOSTICS INC | $9,027,000 | -28.6% | 908,100 | -4.4% | 0.71% | -36.6% |
| ANGO | Sell | ANGIODYNAMICS INC | $6,488,000 | -62.3% | 411,930 | -58.8% | 0.51% | -66.5% |
| MNTA | Sell | MOMENTA PHARMACEUTICALS INC | $4,660,000 | -67.1% | 400,000 | -50.0% | 0.36% | -70.8% |
| CCRN | Sell | CROSS CTRY HEALTHCARE INC | $2,490,000 | -83.8% | 308,542 | -80.0% | 0.20% | -85.6% |
| DSCI | Exit | DERMA SCIENCES INC | $0 | – | -497,000 | -100.0% | -0.47% | – |
| XNPT | Exit | XENOPORT INC | $0 | – | -1,000,000 | -100.0% | -0.51% | – |
| ARWR | Exit | ARROWHEAD RESH CORP | $0 | – | -1,500,000 | -100.0% | -1.44% | – |
| EW | Exit | EDWARDS LIFESCIENCES CORP | $0 | – | -350,000 | -100.0% | -2.03% | – |
| A | Exit | AGILENT TECHNOLOGIES, INC | $0 | – | -500,000 | -100.0% | -2.52% | – |
| MRK | Exit | MERCK & CO. INC NEW | $0 | – | -990,300 | -100.0% | -4.37% | – |
| TEVA | Exit | TEVA PHARMACEUTICAL IND LTDcall | $0 | – | -2,250,000 | -100.0% | -7.95% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.